Price
$43.83+18.14%Social Signal Score
Analyst Ratings
4 analystsRevenue
$371.07M+130.40%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Fred Burke
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 3,600
- Beta
- 0.10
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 12.71
Financials
Revenue
$371.07M+130.4%Net Income
$18.68M+7057.1%EBITDA
$32.09M+421.0%Free Cash Flow
$39.34M+212.9%EPS (diluted)
$0.29+6644.2%Shares Outstanding (diluted)
63.92M+5.0%Operating Expenses
$60.16MCash & Debt
$119.66MReturn of Capital
$0.00Revenue by Segment (annual)
$1.45BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.45B | $49.22M | $0.79 |
| 2024 | $1.23B | $-87.29M | $-1.77 |
| 2023 | $1.05B | $23.90M | $0.39 |
| 2022 | $908.91M | $35.42M | $0.58 |
| 2021 | $792.07M | $16.31M | $0.27 |
| 2020 | $735.96M | $19.94M | $0.33 |
| 2019 | $698.29M | $21.75M | $0.36 |
| 2018 | $600.37M | $14.68M | $0.24 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GRDN's reported EPS growth of 18.6% a year over 7 years.
- EPS in 5 years
- $1.85
- Implied price
- $70.35
- Return from $46.94
- 8.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $34.98 — -25.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 26 | 32 | 38 | 44 | 50 |
|---|---|---|---|---|---|
| 8.6% | -8.0% | -4.1% | -0.7% | 2.2% | 4.9% |
| 13.6% | -3.7% | 0.3% | 3.9% | 6.9% | 9.7% |
| 18.6% | 0.5% | 4.8% | 8.4% | 11.7% | 14.5% |
| 23.6% | 4.7% | 9.2% | 13.0% | 16.4% | 19.4% |
| 28.6% | 9.0% | 13.6% | 17.6% | 21.1% | 24.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
130+62.50%Social Signal Score
Mentions (5)
- Newszacks.com·4d ago·Positive
Guardian Pharmacy Services, Inc. (GRDN) Hits Fresh High: Is There Still Room to Run? Guardian Pharmacy (GRDN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗ - Newsmarketbeat.com·15d ago·Negative
What Guardian Pharmacy Services (GRDN) Said on Its Q3 Earnings Call Guardian Pharmacy Services NYSE: GRDN raised its full-year revenue and adjusted EBITDA guidance after third-quarter profit rose on higher prescription volumes, improved reimbursement and purchasing initiatives, even as drug price reductions weighed on reported revenue.
View source ↗ - Newsbusinesswire.com·20d ago·Negative
Guardian Pharmacy Services, Inc. to Participate in Upcoming Stephens Investment Conference ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that it will attend the Stephens Investment Conference in Nashville, TN, on Wednesday, November 18, 2026. Fred Burke, President and Chief Executive Officer, will participate in a fireside chat at 9:30 a.m. Central Standard Time. Investors, analysts, members of the media and the general public are invited to listen to a …
View source ↗ - Newsbusinesswire.com·95d ago·Negative
…armacy Services, Inc., to Participate in Upcoming Jefferies Healthcare Services Investor Conference ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) today announced that it will participate in the Jefferies Healthcare Services Conference, on Tuesday, September 15, 2026. Fred Burke, President and Chief Executive Officer, will participate in a fireside chat at 2:25 p.m. Central Standard Time that same day. Investors, analysts, members of the media and the general public are …
View source ↗ - Newsmarketbeat.com·106d ago·Negative
Guardian Pharmacy Services Q2 Earnings Call Highlights Guardian Pharmacy Services NYSE: GRDN reported second-quarter revenue growth of 2% year over year to $351.2 million, while adjusted EBITDA increased 19% to $29.7 million, as the company said it continued to offset profitability pressure from Inflation Reduction Act-related drug pricing reductions.
View source ↗
Earnings
Wed, Mar 10(in 4 months)
Consensus estimate $0.45 per share
Typical surprise +4.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.33 vs $0.31beat
- Thu, Aug 6$0.29 vs $0.26beat
- Wed, May 6$0.29 vs $0.24beat
- Wed, Mar 11$0.37 vs $0.27beat
- Mon, Nov 10$0.25 vs $0.24beat
- Mon, Aug 11$0.23 vs $0.22beat
Estimates and results for GRDN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GRDN officers and directors.
- Bought
- $100k
- Sold
- $419.8m
1 trade
14 trades
- Martin David Normansold
- Martin David Normansold
- Martin David Normansold
- Martin David Normansold
- Pharmacy Investors, Llcsold
- Morris David Ksold
- Burke Fredsold
- Forbes Kendallsold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GRDN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
